<DOC>
	<DOCNO>NCT00380913</DOCNO>
	<brief_summary>This study design evaluate safety efficacy Cesamet™ control pain subject experience pain due diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Evaluation Efficacy Cesamet™ Treatment Pain Patients With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>The purpose study determine safety efficacy Cesamet™ symptomatic treatment pain due diabetic peripheral neuropathy . This phase IV , multi-center , open label outpatient clinical trial evaluate Cesamet™ treatment control pain due diabetic peripheral neuropathy . The study two phase : Pretreatment Phase Treatment Phase .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients diabetic peripheral neuropathic pain Chronic daily pain present least 2 month On stable analgesic regimen one month Baseline pain score great 40mm visual analog scale Hypersensitivity compound study drug similar drug Pregnant lactate female Drug alcohol abuse Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>